Reading time is 1 mins
.
.
EVEN CHINA DOESN’T TRUST THE SINOVAC VACCINE: THEY HAVE STARTED DEVELOPING AN MRNA VACCINE
As doubts grow about CORONAVAC, developed by Sinovac, also known as the “China vaccine” in Turkey, it has been announced that China has begun work on developing an mRNA-based vaccine…
Recently, with the increase in cases of the corona virus in China, the effect of inactive vaccines used inside the country has begun to be questioned. With rapid spread of the epidemic that broke out in China, especially in the city of Shian, the effect of inactive vaccines used in the country has begun to be discussed.
The British Financial Times newspaper wrote that the Chinese authorities have taken action for an mRNA-based vaccine, noting that there is growing concern that the vaccine developed by Sinovac, which is also used in Turkey, is ineffective.
“While the process of developing an mRNA-based local vaccine in China is progressing very slowly, they have preferred traditional inactive vaccines,” the Financial Times wrote, adding that the Covid-19-related deaths in the country are very low, along with very strict measures and social isolation implemented in China. In November 2021, the Chinese company Suzhou Abogen Biosciences and the company Walvax received approval to begin work on a joint mRNA vaccine,” the commentary said.
Last month, people in China corona virus in 1,758 after the emergence of a $ 13 million on the move to the city of Sian rate of the authorities that covers Financial Times, “China’s strict measures against the epidemic in Wuhan epidemic during beginning of the biggest show that confidence in vaccines is very low local authorities,” he said.
On the other hand, it was recalled that recent research on Sinovac’s vaccine has shown that the two doses of the vaccine also used in Turkey and the reminder dose do not provide sufficient protection against the Omicron variant.
.
.
.
.
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.